

# The use of electronic health records during the COVID-19 (C19) pandemic: what impact for observational studies not assessing COVID-19?

## Background

### Electronic health records and COVID-19: what recommendations?

Electronic Health Records (EHR) are increasingly used to investigate epidemiologic research questions, as they provide high power and easily available data. Recent studies found a dramatic reduction of healthcare consumptions during the C19 pandemic<sup>1</sup>. Recommendations were published on how to conduct clinical studies during the C19 pandemic, but no equivalents exist for observational studies using EHR<sup>2</sup>.

## Objectives

To provide insights and tentative recommendations on statistical analyses to perform for incoming observational studies not assessing C19 using EHR during the C19 pandemic period.

## Methods

- Sources of bias could occur in the context of C19 pandemic for the measurement of incidence of pathologies and the association between an exposure and an outcome under scrutiny.
- The statistical analyses to evaluate the magnitude of these biases and to account for them will be described.

An illustrative example using surgical data is provided.


## Conclusion

This work highlights the importance of evaluating the impact of C19 even in studies not initially related to C19 because measurement bias can occur and C19 may be a confounding factor or an effect modifier for the associations of interest.

EHR are a powerful tool that should continue to be harnessed to investigate varied medical research questions and not be limited to their already proven usefulness in evaluating the C19 pandemic. While extra care is warranted when examining endpoints unrelated to C19 during the pandemic, statistical tools already exist to carefully address methodological challenges that may arise in observational study settings.

## Results

### Sources of bias



## Recommendations


### Recommendations on design

- Avoid before/after designs (with subjects as their own control) and prefer case-control studies.
- Plan longer follow-back periods ( $\geq 2$  years) to detect comorbidities and medical history in order to prevent the detection only during the C19 period (because an underestimation is likely to occur).
- To have multiple years prior to C19 onset as comparator to evaluate the effect of C19 in incorporating the expected trend in addition to the seasonality difference.

### Description and analysis of C19 impact

- Describe patients included before versus after the C19 period.
- Describe monthly and yearly evolution of number of patients included, main risk factors and outcomes.
- Compute the expected number of patients according to seasonality and compare with the observed number of patients<sup>3</sup>. These differences can be analysed using time series or Poisson regression to formally test the presence of persistent difference.

### Illustrated example on surgeries



### Influence of C19 at the month or the year scale?

#### Low

- Analyses can be pooled on all patients.
- In case of matched analyses, the month of inclusion should be included as a matching variable in order to have similar patients in terms of inclusion during the C19 period.
- In case of survival analyses, a competing risk analysis could be considered using C19-related death as competing event (using proxy of C19-related death).
- All evolution after 2020 versus before should be interpreted with caution as it may be related to the natural evolution of the disease but also to C19.

#### High

- Understand the mechanisms and the causes of these changes (measurement bias, direct influence of C19 on exposure and/or outcome).
- If feasible, restrict primary analyses on the period before C19.
- Sensitivity analyses on pooled patients.

<sup>1</sup> Moynihan, Ray, Sharon Sanders, Zoe A. Michaleff, Anna Mae Scott, Justin Clark, Emma J. To, Mark Jones, et al. « Impact of COVID-19 Pandemic on Utilisation of Healthcare Services: A Systematic Review ». *BMJ Open* 11, no 3 (2021): e045343. <https://doi.org/10.1136/bmjopen-2020-045343>.

<sup>2</sup> Webster-Clark, Michael. « Ways COVID-19 May Impact Unrelated Pharmacoepidemiologic Research Using Routinely Collected Data ». *Pharmacoepidemiology and Drug Safety* 30, no 3 (2021): 400-401. <https://doi.org/10.1002/pds.5182>.

<sup>3</sup> Roland, N., L. Duranteau, F. Cuenot, R. Dray-Spira, A. Weill, et M. Zureik. « Impact de l'épidémie COVID-19 sur l'utilisation des contraceptifs en France en 2020 et jusqu'en avril 2021 ». *Revue D'Epidémiologie et De Santé Publique* 70 (mars 2022): 520. <https://doi.org/10.1016/j.respe.2022.01.095>.